Casting a wider net for cancer subjects
With the number of cancer studies soaring, sponsors now need to look further
afield for subjects. GCPj discusses how to plan these studies while minimising the risk to sponsors.
New rules for registrations GCPj guides readers through the new compliance requirements of clinicaltrials.gov
laid out in the US FDA Amendment Act.
Harness the power of intelligence Accessing historic data to support new drug findings is difficult. Can 'intelligence
networks' help utilise metadata and improve drug safety.
------------------------------------------------------
Good science equals good business GCPj describes the art of good science in Phase IV and ways to design successful
post-marketing studies.
------------------------------------------------------
Making project teams work People or 'soft skills' in project management are often overlooked. GCPj offers companies tips to bring out the best in their project teams.
